Next Article in Journal
Vesiculated Long Non-Coding RNAs: Offshore Packages Deciphering Trans-Regulation between Cells, Cancer Progression and Resistance to Therapies
Next Article in Special Issue
PlantRNA_Sniffer: A SVM-Based Workflow to Predict Long Intergenic Non-Coding RNAs in Plants
Previous Article in Journal / Special Issue
CirComPara: A Multi‐Method Comparative Bioinformatics Pipeline to Detect and Study circRNAs from RNA‐seq Data
Review

RNA Biomarkers: Frontier of Precision Medicine for Cancer

MOE Key Laboratory of Bioinformatics, Tsinghua‐Peking Joint Center for Life Sciences, Center for Plant Biology and Center for Synthetic and Systems Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China
*
Author to whom correspondence should be addressed.
Non-Coding RNA 2017, 3(1), 9; https://doi.org/10.3390/ncrna3010009
Received: 30 December 2016 / Accepted: 13 February 2017 / Published: 20 February 2017
(This article belongs to the Special Issue Bioinformatics Softwares and Databases for Non-Coding RNA Research)
As an essential part of central dogma, RNA delivers genetic and regulatory information and reflects cellular states. Based on high‐throughput sequencing technologies, cumulating data show that various RNA molecules are able to serve as biomarkers for the diagnosis and prognosis of various diseases, for instance, cancer. In particular, detectable in various bio‐fluids, such as serum, saliva and urine, extracellular RNAs (exRNAs) are emerging as non‐invasive biomarkers for earlier cancer diagnosis, tumor progression monitor, and prediction of therapy response. In this review, we summarize the latest studies on various types of RNA biomarkers, especially extracellular RNAs, in cancer diagnosis and prognosis, and illustrate several well‐known RNA biomarkers of clinical utility. In addition, we describe and discuss general procedures and issues in investigating exRNA biomarkers, and perspectives on utility of exRNAs in precision medicine. View Full-Text
Keywords: biomarker; exRNA; precision medicine; cancer biomarker; exRNA; precision medicine; cancer
Show Figures

Figure 1

MDPI and ACS Style

Xi, X.; Li, T.; Huang, Y.; Sun, J.; Zhu, Y.; Yang, Y.; Lu, Z.J. RNA Biomarkers: Frontier of Precision Medicine for Cancer. Non-Coding RNA 2017, 3, 9. https://doi.org/10.3390/ncrna3010009

AMA Style

Xi X, Li T, Huang Y, Sun J, Zhu Y, Yang Y, Lu ZJ. RNA Biomarkers: Frontier of Precision Medicine for Cancer. Non-Coding RNA. 2017; 3(1):9. https://doi.org/10.3390/ncrna3010009

Chicago/Turabian Style

Xi, Xiaochen, Tianxiao Li, Yiming Huang, Jiahui Sun, Yumin Zhu, Yang Yang, and Zhi J. Lu. 2017. "RNA Biomarkers: Frontier of Precision Medicine for Cancer" Non-Coding RNA 3, no. 1: 9. https://doi.org/10.3390/ncrna3010009

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop